Endocrinology Vol. 140, No. 9 3890-3903
Copyright © 1999 by The Endocrine Society
Interleukin-6 Is a Needed Proinflammatory Cytokine in the Prolonged Neural Activity and Transcriptional Activation of Corticotropin-Releasing Factor during Endotoxemia1
Luc Vallières2 and
Serge Rivest3
Laboratory of Molecular Endocrinology, CHUL Research Center and
Department of Anatomy and Physiology, Laval University, Sainte-Foy,
Québec, Canada G1V 4G2
Address all correspondence and requests for reprints to: Dr. Serge Rivest, Laboratory of Molecular Endocrinology, CHUL Research Center, 2705 Laurier boulevard, Sainte-Foy, Québec, Canada G1V 4G2. E-mail: serge.rivest{at}crchul.ulaval.ca
 |
Abstract
|
|---|
Interleukin-6 (IL-6) is a proinflammatory cytokine that plays multiple
roles in the central nervous system during infections and injuries.
Although this molecule is capable of stimulating the release of ACTH
and glucocorticoids, it has been demonstrated that a single injection
of IL-6 fails to activate the paraventricular nucleus (PVN) neurons
that control the hypothalamic-pituitary-adrenal axis. The observation
that IL-6 receptor (IL-6R) is up-regulated in the brain during
endotoxemia led us to hypothesize that prior induction of IL-6R
synthesis could amplify the effect of circulating IL-6 on the
neuroendocrine response. Rats received a first iv injection of either
bacterial lipopolysaccharide (LPS; 5 µg) or vehicle solution. After a
6-h waiting period, they received a second iv injection of either
recombinant rat IL-6 or vehicle solution and were killed 1 h
thereafter. Using in situ hybridization, we observed
that IL-6R was barely expressed in the PVN under basal conditions, but
was rapidly produced in response to LPS. IL-6 itself was also able to
induce the synthesis of its own receptor along cerebral blood vessels,
and this effect extended to several parenchymal structures, including
the PVN, when the cytokine was administrated after LPS. In agreement
with our hypothesis, we found that IL-6 injected in LPS-pretreated rats
stimulated PVN neurons, as revealed by the expression of CRF primary
transcript and c-fos messenger RNA, an immediate early
gene used as a marker of cellular activation. A significant increase in
plasma corticosterone levels was also found in animals that received iv
IL-6 injection after being pretreated 6 h before with the very low
dose of LPS. The fact that IL-6 alone or injected after LPS treatment
was unable to induce cyclooxygenase-2 synthesis is an argument in favor
of a PG-independent mechanism. The relative contribution of IL-6 in
stimulating CRF expression in the PVN and neural activity throughout
the brain during endotoxemia was also investigated in IL-6-deficient
mice after an ip injection of LPS. The endotoxin induced similar
c-fos and CRF expression patterns in knockout and
wild-type mice, but the expression levels were generally higher and/or
lasted longer in wild-type animals. Taken together, physiological
changes that may include the induction of IL-6R synthesis seem to be
necessary for IL-6 to activate PVN neurons. Moreover, although IL-6
does not appear essential during the early phases of endotoxemia, this
cytokine is required during the later phases to prolong the activation
of neural cells throughout the brain and to maintain CRF expression in
the PVN neurons that control the hypothalamic-pituitary-adrenal axis.
 |
Introduction
|
|---|
BACTERIAL septic shock is a serious
pathological state often caused by certain Gram-negative bacteria and
characterized by numerous physiological changes, such as fever,
hypotension, and secretion of a variety of hormones. This toxicity is
due to a component of the bacterial cell wall, the endotoxin
lipopolysaccharide (LPS), that stimulates monocytes and macrophages to
produce proinflammatory cytokines. In addition to their classic roles
in modulating the immune and inflammatory responses, these pleiotropic
factors can also act within the nervous system to solicit local and
systemic changes necessary to restore homeostasis. Recent evidence
indicates that different cell populations in the brain can synthesize
their own set of cytokines during endotoxemia, in particular
interleukin-6 (IL-6), IL-1ß, and tumor necrosis factor-
(TNF
)
(1, 2, 3). Among their central effects, the induction of fever and the
activation of the hypothalamic-pituitary-adrenal (HPA) axis have been
widely investigated because of their major impacts on the inflammatory
processes (4, 5, 6).
IL-6 has been defined as one of the principal endogenous pyrogens
from the observations that IL-6-deficient mice are unable to develop
normal fever in response to both LPS and IL-1ß (7). Based on
physiological and neuroanatomical studies, it has been proposed that
IL-6 may induce fever by signaling thermoregulatory neurons of the
anterior hypothalamic area through PG-dependent pathways (8, 9, 10). On
the other hand, the relative contribution of IL-6 to modulating the HPA
axis during endotoxemia and its exact mechanisms of action are not yet
fully understood. It has been shown that IL-6 can increase
glucocorticoid production by stimulating the secretion of ACTH from the
anterior pituitary (11, 12) and by acting directly on the adrenal gland
(13, 14, 15). Although IL-6 can also trigger the release of CRF into the
hypophyseal portal system (16, 17, 18), this cytokine seems unable, in
contrast to IL-1ß, to induce neuronal activation and CRF gene
transcription in the hypothalamic paraventricular nucleus (PVN) (10, 19), a region that contains neuroendocrine CRF neurons. This lack of
effect might, however, be explained by the fact that IL-6 receptor
(IL-6R) is not expressed in this nucleus under basal conditions (1). It
is plausible that the induction of IL-6R synthesis may be an essential
step taking place early during inflammation to allow IL-6, when it
becomes available in the blood circulation, to trigger neural
responses. We, therefore, hypothesized that this event may potentiate
and amplify the action of systemic IL-6 on the CRF-containing neurons
that control the HPA axis.
Besides fever and CRF secretion, IL-6 may also influence a
variety of other neural functions during endotoxemia. This attractive
possibility is suggested by the observations that IL-6 is synthesized
by the circumventricular organs and secreted into cerebrospinal fluid
in response to systemic LPS administration (1, 20) and that an
intracerebroventricular injection of IL-6 induces widespread cellular
activation in the brain, particularly over the ependymal cell layer,
the ventricular walls, and the meninges (10). One possible role of IL-6
is the modulation of certain properties of the endothelial and
ependymal cells, which express the IL-6R subunits (1) and constitute
natural barriers against immunological substances present in the
circulation and cerebrospinal fluid, respectively. It has been
demonstrated that IL-6 participates in the development of reactive
gliosis affecting both microglia and astrocytes (21, 22, 23). This response
may be essential to eliminate and restrain the penetration of
circulating LPS into the nervous tissue. Furthermore, new findings
suggest that IL-6 may play neuroprotective functions, as, for example,
the repression of TNF
-induced neurotoxic inflammation and the
enhancement of nerve growth factor signaling (24, 25).
In this study, we have evaluated the contribution of IL-6 in
stimulating neural activity and CRF gene transcription in rodent brains
during endotoxemia. Given that IL-6R has been shown to be up-regulated
in response to endotoxin (1), we first characterized its expression
pattern in the brain and verified whether CRF neurons of the PVN
produced this receptor after different treatments with LPS and IL-6. To
verify the possibility that preinduction of IL-6R synthesis may
increase the influence of IL-6 on neuroendocrine functions, we further
compared the effects of a systemic injection of IL-6 on the PVN when
given under basal conditions and 6 h after pretreatment with low
dose LPS. To confirm and complement the results obtained with this
approach, we finally used IL-6-deficient mice to analyze the role of
IL-6 in the activation of neural cells, a phenomenon commonly observed
in the PVN and elsewhere in the brain during endotoxemia. We provide
here evidence that IL-6 modulates, under LPS challenge, the expression
of its own receptor, the neuroendocrine CRF, and the protooncogene
c-fos, an immediate early gene used as a marker of cellular
activation. In addition, we demonstrate that IL-6 is unable to
stimulate the gene encoding the enzyme cyclooxygenase-2 (COX-2)
normally required for PG production.
 |
Materials and Methods
|
|---|
Animals
The experiments were performed on adult male Sprague Dawley rats
(275300 g) and IL-6 knockout and wild-type mice of the C57BL/6 line
(2030 g). The mutant mice were provided by Dr. M. Kopf (Basel
Institute for Immunology, Basel, Switzerland) and generated as
previously described (26). All animals were housed individually under
standard laboratory conditions (14-h light, 10-h dark cycle; lights on
at 0600 h) with food and water available ad libitum. A
total of 16 rats was assigned to 4 different treatments (injection of
vehicle plus vehicle, LPS plus vehicle, vehicle plus IL-6, and LPS plus
IL-6), and 24 mice were divided into 8 groups (knockout and wild-type
mice killed before or 1, 4, and 8 h after LPS administration). The
experiments were repeated at least twice to confirm the data, although
animals of two different sets of studies were not pooled together. All
protocols were approved by the Laval Universitys animal welfare
committee.
iv injection of LPS and IL-6 in rats
A catheter containing sterile pyrogen-free heparin-saline (5.0
U/ml) was implanted into the right jugular vein of rats anesthetized
with an ip injection (300 µl) of a mixture of ketamine hydrochloride
(91 mg/ml) and xylazine (9 mg/ml). The catheter was made from a piece
of SILASTIC brand tubing (SILASTIC medical grade tubing, 0.50 mm
i.d., 0.94 mm o.d.; Dow Corning Corp., Midland, MI)
connected to Intramedic polyethylene tubing (id, 0.58 mm; od, 0.965 mm;
PE-50, Clay Adams, Parsippany, NJ). The internal SILASTIC tip of the
catheter was positioned at the atrium, and the outlet was placed at an
interscapular position and sealed. After the surgery, the animals were
kept individually for a 5-day recuperation period.
On the day of the experiment (0900 h), the outlet of the catheter was
fastened to a truncated 27-gauge needle attached to PE-50 tubing. This
connector was then fixed to a 1-ml syringe, and the rats were placed
individually in a quiet room for at least 2 h before
experimentation. This procedure was used to avoid disturbing the
animals during the injections. Rats received first an iv injection of
either LPS (5 µg dissolved in 300 µl 0.9% sterile pyrogen-free
saline; from Escherichia coli, serotype 055:B5, catalog no.
L2880, Sigma Chemical Co., Oakville, Canada) or vehicle
solution. The animals were conscious and freely moving during the
procedure. After a 6-h waiting period, they received a second iv
injection of either recombinant rat IL-6 (1.5 µg dissolved in 300
µl sterile pyrogen-free distilled water; bioactivity,
1 x
107 U/mg; endotoxin, <0.1 ng/µl; catalog no. PRC0065,
lot H032506, BioSource Technologies, Inc., Camarillo, CA)
or vehicle solution. The animals were killed 1 h after the second
injection with an iv injection of ketamine-xylazine. Tissue processing
was performed as described below.
ip injection of LPS in mice
In the morning (at
0830 h), IL-6 knockout and wild-type mice
received an ip injection of LPS (25 µg dissolved in 100 µl 0.9%
sterile pyrogen-free saline). All animals were conscious and freely
moving during the procedure and were kept individually in their cages.
The mutant mice seemed less affected by LPS, showing higher locomotor
activity than wild-type controls. The animals were killed 1, 4, and
8 h after LPS administration with an ip injection of
ketamine-xylazine. Additional mice were not injected with LPS and were
used as controls (time zero). Tissue processing was performed as
described below.
Tissue processing
All animals were rapidly perfused transcardially with 0.9%
saline followed by ice-cold 4% paraformaldehyde in 100 mM
borax buffer (pH 9.5). Their brains were removed, postfixed with fresh
4% paraformaldehyde for 25 days at 4 C, and placed in the same
fixative containing 10% sucrose overnight at 4 C. They were mounted
onto a microtome (Reichert-Jung, Cambridge Instrument Co., Deerfield,
IL), frozen with dry ice, and cut into 30-µm (rats) or 20-µm (mice)
coronal sections from the olfactory bulb to the caudal medulla. The
slices were collected in a cold cryoprotectant solution [50
mM sodium phosphate buffer (pH 7.3), 30% ethylene glycol,
and 20% glycerol] and stored at -20 C until histochemical
analysis.
Riboprobe synthesis and preparation
Details of the plasmids and enzymes used for complementary RNA
(cRNA) probe synthesis are presented in Table 1
. Rat c-fos complementary DNA
(cDNA) was obtained from Dr. I. Verma (The Salk Institute, La Jolla,
CA), rat CRF cDNA from Dr. K. Mayo (Northwestern University, Evanston,
IL), rat intronic CRF cDNA from Dr. S. Watson (University of Michigan,
Ann Arbor, MI), rat COX-2 cDNA from Dr. K. Peri (Sainte-Justine
Hospital Research Center, Montréal, Canada), and rat IL-6 cDNA
from American Type Culture Collection (Manassas, VA). All
protocols were adapted from Simmons et al. (27). Sense and
antisense radioactive cRNA copies were synthesized by incubating 250 ng
linearized plasmid in 6 mM MgCl2, 40
mM Tris (pH 7.9), 2 mM spermidine, 10
mM NaCl, 10 mM dithiothreitol, 0.2
mM ATP/GTP/CTP, [
-35S]UTP, 40 U RNAsin
(Promega Corp., Madison, WI), and 20 U of the appropriate
RNA polymerase (Table 1
) for 60 min at 37 C. The unincorporated
nucleotides were removed by adding 100 µl deoxyribonuclease solution
(1 µl deoxyribonuclease, 5 µl 5 mg/ml transfer RNA, and 94 µl 10
mM Tris-10 mM MgCl2) for 10 min,
followed by phenol-chloroform extraction. The probes were precipitated
with 80 µl 5 M ammonium acetate and 500 µl 95% ethanol
for 20 min on dry ice. After centrifugation, the pellets were washed
with 500 µl 70% ethanol, dried, and resuspended in 100 µl 10
mM Tris/1 mM EDTA. The probes (107
cpm/ml) were mixed into an appropriate volume of hybridization solution
[822 µl solution 1 (500 µl formamide; 60 µl 5 M
NaCl; 10 µl 1 M Tris, pH 8.0; 2 µl 0.5 M
EDTA, pH 8.0; 20 µl 50 x Denharts solution; 200 µl 50%
dextran sulfate; and 30 µl diethylpyrocarbonate (depc) water), 50
µl 10 mg/ml transfer RNA, and 10 µl 1 M dithiothreitol
(118 µl depc water - volume of probe used)] and heated for 5
min at 65 C before being spotted on the slides (100 µl). Radioactive
sense cRNA copies (controls) were also prepared to verify the
specificity of each probe.
In situ hybridization histochemistry
In situ hybridization was performed to localize each
transcript [c-fos, CRF, heteronuclear (hn) CRF, IL-6R, and COX-2
messenger RNAs (mRNAs)] on every sixth section from the olfactory
bulb to the end of the medulla. All solutions were treated with depc
and sterilized to prevent RNA degradation. The slices were washed in 50
mM potassium PBS (KPBS), mounted onto gelatin- and
poly-L-lysine-coated slides, and vacuum-dried. They were
fixed in 4% paraformaldehyde for 20 min and digested by proteinase K
(10 µg/ml in 100 mM Tris-HCl, pH 8.0, and 50
mM EDTA, pH 8.0) at 37 C for 25 min. The sections were then
rinsed in sterile depc water followed by a solution of 100
mM triethanolamine (pH 8.0), acetylated in 0.25% acetic
anhydride in 100 mM triethanolamine, and dehydrated through
graded concentrations of alcohol (50%, 70%, 95%, and 100%). After
vacuum drying, 100 µl hybridization mixture (106 cpm)
were spotted on each slide, sealed under a coverslip, and incubated at
60 C for 1520 h on a slide warmer. The coverslips were then removed,
and the slides were rinsed four times in 4 x SSC (150
mM NaCl and 15 mM Tris-NaCl citrate buffer, pH
7.0) at room temperature. The sections were digested by ribonuclease A
(20 µg/ml in a solution of 500 mM NaCl; 10 mM
Tris-HCl, pH 8.0; and 1 mM EDTA, pH 8.0) at 37 C for 30
min, rinsed in descending concentrations of SSC (2, 1, and 0.5 x),
washed in 0.1 x SSC for 30 min at 60 C, and dehydrated through
graded concentrations of alcohol. After being vacuum-dried, the
sections were exposed at 4 C to x-ray films (Eastman Kodak Co.) for 17 h (c-fos and CRF), 65 h (IL-6R
and COX-2), or 96 h (hnCRF), defatted in xylene, and dipped into
NTB2 nuclear emulsion (Eastman Kodak Co.; diluted 1:1 with
distilled water). Slides were exposed for 7 days (c-fos and
CRF), 14 days (IL-6R and COX-2), or 21 days (hnCRF); developed in D19
developer (Eastman Kodak Co.) for 3.5 min at 1416 C;
washed for 15 sec in water; and fixed in rapid fixer (Eastman Kodak Co.) for 5 min. Thereafter, the tissues were rinsed under
running distilled water for 1 h, counterstained with thionin
(0.25%), dehydrated through graded concentrations of alcohol, cleared
in xylene, and coverslipped with DPX (BDH, Poole, UK).
Dual labeling
Immunohistochemistry and in situ hybridization were
combined to determine whether CRF neurons of the PVN expressed IL-6R
mRNA. Hypothalamic sections were stained for CRF using the
avidin-biotin amplification bridge method with peroxidase as a
substrate. The slices were washed in sterile depc-treated KPBS at room
temperature and incubated for 2 h with rabbit antihuman/rat CRF
serum (diluted 1:20,000; code PBL rC70; provided by Dr. W. Vale,
Peptide Biology Laboratory, The Salk Institute, La Jolla, CA) mixed in
KPBS containing 0.4% Triton X-100 and 0.25% heparin sodium salt USP.
The sections were then washed in KPBS and incubated for 1 h with
biotinylated goat antirabbit IgG (diluted 1:1500; Vector Laboratories, Inc. Burlingame, CA) mixed in KPBS containing
0.4% Triton X-100 and 0.25% heparin sodium salt USP. The slices were
then rinsed with KPBS and incubated for 1 h with an
avidin-biotin-peroxidase complex (Vectastain ABC elite
kit, Vector Laboratories, Inc., Burlingame, CA). After
several washes, the brain slices were reacted in KPBS containing 0.05%
3,3'-diaminobenzidine tetrahydrochloride and 0.003% hydrogen peroxide
(H2O2). Thereafter, the slices were rinsed with
KPBS, mounted onto gelatin- and poly-L-lysine-coated
slides, and vacuum-dried. In situ hybridization was
performed as described above to localize IL-6R mRNA, except that the
steps with alcohol were shortened (10 dips) to avoid decoloration of
immunostained cells.
Blood sampling and corticosterone measurement in rats
Blood was collected quickly by cardiac puncture before
perfusion, transferred in EDTA tubes (Becton Dickinson and Co., Franklin Lakes, NJ), and centrifuged for 10 min at 3000 rpm
(4 C). Plasma was collected and stored at -20 C until the analysis.
Corticosterone levels were measured by RIA (Immuchem corticosterone RIA
kit for rats, ICN Biomedicals, Inc., Costa Mesa, CA)
according to the manufacturers protocol. The intra- and interassay
coefficients of variation were both 7%.
OD analysis
Semiquantitative analysis of hybridization signals for
c-fos, CRF, hnCRF, and IL-6R mRNAs was carried out on x-ray
films over at least two hypothalamic paraventricular nuclei (bilateral)
for each animal. Transmittance values (referred here as OD) of the
hybridization signals were measured on a Northern Light Desktop
Illuminator (Imaging Research, Inc.) using a Sony Camera
Video System fastened to a MicroNikkor 55-mm Vivitar extension tube
set for Nikon lens and coupled to a Macintosh computer
(Power Macintosh 7100/66) and the NIH Image software version 1.59/ppc
(written by W. Rasband at the NIH and available from the internet by
anonymous ftp from zippy.nih.gov). The OD values for each pixel were
calculated using a known standard of intensity and distance
measurements from a logarithmic specter adapted from Bioimage Visage
110s (Millipore Corp., Ann Arbor, MI). The wedge was
calibrated before correcting for film saturation, which was determined
by sampling darkest PVNs and adjusting the light source and exposure
time. All samples displaying clear positive signals were evaluated
within the linear OD curve to avoid pixel saturation and
underestimation. Sections from experimental and control animals were
digitized and subjected to densitometric analysis, yielding
measurements of mean density per area. The OD of each side of the PVN
(bilateral) was then corrected for the average background signal by
subtracting the OD of areas without positive signal located immediately
outside the digitized nucleus. Because of the lack of basal expression
of c-fos mRNA and CRF hnRNA in the PVN, the stained slides
were used to delineate the nucleus on the film. Data are expressed as
the mean ± SEM and were analyzed by two-way ANOVA
followed by the Bonferroni/Dunn test used for post-hoc
comparisons when appropriate.
Qualitative analysis
Anatomical identification of brain structures was based on the
Swansons atlas (28). The relative intensity of c-fos mRNA
signals throughout mouse brains was assessed on x-ray film images and
graded according to the scale of undetectable (-), low (+), moderate
(2+), strong (2++), or very strong (2+2+).
 |
Results
|
|---|
IL-6R mRNA is up-regulated in response to LPS and IL-6
We have previously described the distribution of IL-6R mRNA in rat
brain and its regulation during endotoxemia (1). To confirm these
results and verify whether IL-6 can modulate the synthesis of its own
receptor, we examined the expression of IL-6R mRNA by in
situ hybridization after different treatments with LPS and IL-6.
Consistent with our previous results, IL-6R mRNA was found in several
brain regions under basal conditions, including the ependymal cell
layer, vascular organ of the lamina terminalis (OVLT), cerebral cortex
(CC), bed nucleus of the stria terminalis (BNST), subfornical organ
(SFO), hippocampus, central nucleus of the amygdala (CeA), median
eminence (ME), and area postrema (AP; Fig. 1
, Veh+Veh). This transcript, however,
was undetectable or very slightly expressed in the PVN of
vehicle-treated animals. The IL-6R mRNA levels increased 7 h after
LPS administration in the OVLT, CC, BNST, PVN, and CeA (Fig. 1
, LPS+Veh). Interestingly, IL-6 was also capable of activating the gene
encoding its receptor. This effect was restricted to blood vessels
after a single injection of IL-6 (Fig. 1
, Veh+IL-6, and Fig. 2
), but extended to the above-mentioned
structures when the cytokine was injected 6 h after LPS
administration (Fig. 1
, LPS+IL-6). Indeed, IL-6 injection induced a
more pronounced expression of its receptor in several regions of the
parenchyma of rats pretreated with the endotoxin. In particular, the OD
analysis of hybridization signals revealed that the IL-6R mRNA levels
in the PVN were significantly higher (P < 0.05) after
treatment with LPS and IL-6 together than after LPS or IL-6 alone (Fig. 3
). Adjacent sections hybridized with a
sense probe did not exhibit positive signal in any of the regions
expressing the transcript with the antisense probe.

View larger version (112K):
[in this window]
[in a new window]
|
Figure 1. Distribution of IL-6R mRNA in rat brains after
different treatments with LPS and IL-6. Rats first received an iv
injection of either 5 µg LPS or vehicle solution. After a 6-h waiting
period, they received a second iv injection of either 1.5 µg IL-6 or
vehicle solution. The animals were killed 1 h afterward, and
in situ hybridization was performed to detect IL-6R
mRNA. bv, Blood vessel; CER, cerebellar cortex; epc, ependymal cell
layer; HP, hippocampus; PIR2, layer 2 of the piriform area; Veh,
vehicle.
|
|

View larger version (54K):
[in this window]
[in a new window]
|
Figure 2. Localization of IL-6R mRNA in cerebral blood
vessels after different treatments with LPS and IL-6. Rats first
received an iv injection of either 5 µg LPS or vehicle solution.
After a 6-h waiting period, they received a second iv injection of
either 1.5 µg IL-6 or vehicle solution. The animals were killed
1 h afterward, and in situ hybridization was
performed to detect IL-6R mRNA. These darkfield photomicrographs show
representative examples of hybridization signals along vascular cells
in rats treated with either IL-6 alone (C) or both LPS and IL-6 (D),
whereas no positive cells were detected in vehicle-injected rats (A).
Additional control animals were treated with LPS during 3 h, and
strong hybridization signals for IL-6R mRNA were observed along blood
vessels (B). The sections were taken from thalamic areas.
Magnification, x25.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
Figure 3. Expression of IL-6R mRNA in the PVN after
different treatments with LPS and IL-6. Rats first received an iv
injection of either 5 µg LPS or vehicle solution. After a 6-h waiting
period, they received a second iv injection of either 1.5 µg IL-6 or
vehicle solution. The animals were killed 1 h afterward, and
in situ hybridization was performed to detect IL-6R
mRNA. OD analysis of hybridization signals was performed on x-ray
films, and data represent the mean ± SEM of four
animals per group. *, P < 0.05 compared with
vehicle-treated animals. **, P < 0.05 compared
with all other groups.
|
|
The expression pattern of IL-6R over the parvocellular division of the
PVN (Fig. 4B
) led us to believe that
CRF-containing cells might express this receptor. The dual labeling
experiment revealed that few CRF-labeled perikarya were positive for
the IL-6R transcript in response to LPS and IL-6 (Fig. 4C
). However,
the IL-6R transcript was very sensitive to the immunohistochemical
procedures, making evaluation of the exact proportion of double labeled
cells difficult. The possibility that other cell types, such as
microglia, express this receptor cannot be ruled out.

View larger version (77K):
[in this window]
[in a new window]
|
Figure 4. Expression of IL-6R mRNA in CRF-containing neurons
of the PVN during endotoxemia. These photomicrographs show
hybridization signals for IL-6R mRNA in the PVN (B) and within CRF
neurons (C) after treatment with both LPS and IL-6. This transcript was
undetectable in the PVN of control animals (A). Magnification, x25 in
A and B; x250 in C.
|
|
IL-6 stimulates the PVN and plasma corticosterone release during
endotoxemia
Based on the above observations, we hypothesized that IL-6
signaling could be enhanced during endotoxemia after the induction of
IL-6R synthesis. We therefore compared the effects of IL-6 on the
expression of different genes in the PVN when injected alone and 6
h after induction of the immune response with LPS. To this end,
c-fos mRNA was used as a marker of cellular activation, and
CRF hnRNA was used as an index of de novo CRF gene
transcription. The time was chosen on the basis of preliminary data
showing that the levels of both transcripts increased 1 h after
LPS injection and declined at 3 h, and CRF hnRNA returned to basal
levels at 6 h (data not shown). As expected, c-fos mRNA
and CRF hnRNA were expressed at very low levels in the PVN of vehicle-
and IL-6-treated rats (Fig. 5
). Moderate
levels of c-fos mRNA were still observed in the PVN 7 h
after LPS injection, whereas CRF hnRNA was barely detectable.
Confirming our hypothesis, both transcripts were significantly
(P < 0.05) higher in the PVN of rats treated with both
LPS and IL-6 than in the animals treated with either LPS or IL-6 alone
(Fig. 5
, A and B). Plasma corticosterone levels were also significantly
higher in animals presensitized and receiving a single iv bolus of
recombinant IL-6 than vehicle- and LPS-injected rats (Fig. 5C
).
However, the Bonferroni post-hoc analysis did not reveal a
significant difference between the circulating corticosterone
concentrations of animals that were injected only with IL-6 (Veh+IL-6)
and those of vehicle-treated rats (Veh+Veh).

View larger version (14K):
[in this window]
[in a new window]
|
Figure 5. c-fos mRNA (A) and CRF
heteronuclear (hn) RNA (B) expression in the PVN of the rat
hypothalamus and plasma corticosterone levels (C) after different
treatments with LPS and IL-6. Rats first received an iv injection of
either 5 µg LPS or vehicle solution. After a 6-h waiting period, they
received a second iv injection of either 1.5 µg IL-6 or vehicle
solution. The animals were killed 1 h afterward, and in
situ hybridization was performed to detect each transcript. OD
analysis of hybridization signals was performed on x-ray films, and
data represent the mean ± SEM of four animals per
group. *, P < 0.05 compared with vehicle-treated
animals. **, P < 0.05 compared with all other
groups.
|
|
It has been demonstrated that IL-6 is insufficient in itself to induce
the expression of the mRNA encoding the enzyme COX-2 necessary for PG
synthesis during inflammation (29). Here we verified whether IL-6 can
stimulate the synthesis of COX-2 mRNA after pretreatment with LPS.
COX-2 mRNA was constitutively expressed in the hippocampus, increased
along blood vessels 3 h after LPS injection, and returned to basal
levels 6 h thereafter. In agreement with previous results, COX-2
mRNA was not induced by IL-6 when injected alone or in combination with
LPS (data not shown).
IL-6 is necessary for the prolonged stimulation of neural activity
during endotoxemia
It has been commonly observed that LPS induces widespread neural
activation in both rat and mouse brains (30). To verify the
contribution of IL-6 to this response and to confirm its involvement in
stimulating the PVN during endotoxemia, we compared the effects of LPS
on c-fos and CRF expression in the brains of IL-6-deficient
and wild-type mice. Table 2
describes the
qualitative analysis of hybridization signals for c-fos mRNA
in mice killed before or 1, 4, and 8 h after LPS administration.
As shown in Fig. 6A
, the
distribution and the intensity of c-fos mRNA hybridization
signals were similar in wild-type and knockout mice under basal
conditions (0 h). One hour after LPS administration, increased levels
of c-fos mRNA were observed in several nuclei without a
difference between knockout mice and their controls, namely the CC,
BNST, medial preoptic area (MPO)/OVLT, SFO, PVN, supraoptic nucleus
(SON), ME, CeA, dorsomedial hypothalamic nucleus, locus coeruleus (LC),
AP, nucleus of the solitary tract, blood vessels, choroid plexus,
leptomeninges, and parabrachial nucleus (Fig. 6A
). Interestingly, we
found that c-fos mRNA expression was markedly reduced in
knockout mice 4 h after LPS injection, but remained elevated in
several brain regions of wild-type animals (Fig. 6B
). These regions
were the ependymal cell layer, which did not express c-fos
mRNA at any time in IL-6-deficient mice, the PVN, CC, LC, MPO/OVLT, ME,
leptomeninges, SFO, submeningual zone (sm), and SON (Table 2
). In the
PVN, the OD analysis indicated that the mRNA encoding c-fos
was indeed significantly higher (P < 0.05) in
wild-type mice than in knockout animals at 4 h post-LPS injection
(Fig. 7A
). In wild-type mice,
c-fos mRNA levels decreased and reached levels observed in
knockout animals at 8 h postinjection, except in the locus
coeruleus, where the message remained elevated (Fig. 6B
).
View this table:
[in this window]
[in a new window]
|
Table 2. Expression of c-fos mRNA in brains of
IL-6-knockout (KO) and wild-type (WT) mice before and after an ip
injection of LPS
|
|


View larger version (243K):
[in this window]
[in a new window]
|
Figure 6. Distribution of c-fos mRNA in
brains of IL-6 knockout (KO) and wild-type (WT) mice during endotoxemia
(A and B). The transcript was detected by in situ
hybridization in brains collected before or 1, 4, and 8 h after an
ip injection of 25 µg LPS. CER, cerebellar cortex; DMH, dorsomedial
hypothalamic nucleus; epc, ependymal cell layer; HP, hippocampus; ICe,
external nucleus of the inferior colliculus; NTS, nucleus of the
solitary tract; PG, pontine gray; PIR2, layer 2 of the piriform area;
PVT, thalamic paraventricular nucleus; sm, submeningual zone.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
Figure 7. Expression of c-fos (A) and CRF (B)
mRNAs in the PVN of IL-6 knockout (KO) and wild-type (WT) mice during
endotoxemia. Each transcript was detected by in situ
hybridization in brains collected before or 1, 4, and 8 h after an
ip injection of 25 µg LPS. OD analysis of hybridization signals was
performed on x-ray films, and data represent the mean ±
SEM of three or four animals per group.
|
|
On the other hand, CRF mRNA progressively increased in the PVN after
LPS injection in both wild-type and knockout animals (Fig. 7B
).
Statistical analysis of OD data showed a significant difference
(P = 0.0365) between the IL-6-deficient and control
mice. Indeed, the CRF mRNA levels in the PVN were generally higher in
wild-type than in knockout mice.
 |
Discussion
|
|---|
This study was undertaken to determine to what degree IL-6
contributes to the stimulation of CRF expression in the PVN and neural
activity throughout the brain during endotoxemia. We first report that
IL-6R is barely expressed in the PVN under basal conditions, but is
constitutively produced in several other brain areas. Although IL-6R
expression can be controlled by IL-6 itself, the synthesis of IL-6R
mRNA is increased in parenchymal structures, such as the PVN, only in
response to bacterial LPS. These observations suggest that IL-6
signaling is enhanced during endotoxemia and led us to hypothesize that
IL-6 could modulate PVN functions after induction of its receptor.
Indeed, our subsequent results confirm that IL-6 can activate PVN
neurons after pretreatment with LPS by stimulating c-fos and
CRF gene transcription as well as plasma corticosterone release. Using
a dual labeling technique, we found that some CRF neurons express
IL-6R, suggesting that IL-6 may directly target these cells to trigger
neuronal activation and CRF secretion. The fact that IL-6 is unable to
induce COX-2 synthesis during this process is an argument in favor of a
PG-independent mechanism. In addition, evidence obtained from the
experiment with mutant animals indicates that LPS induces similar CRF
and c-fos expression patterns in wild-type and
IL-6-deficient mice. However, the expression levels are generally
higher and remain elevated longer in wild-type animals, particularly in
the PVN and over structures close to the ventricles. We, therefore,
propose that IL-6, although not involved during the initial phases of
endotoxemia, seems necessary during the later phases for maintaining
the stimulation of CRF neurons controlling the HPA axis and for
prolonging the activation of neural cells throughout the brain. This
phenomenon might be of great importance to protect the brain and to
restore homeostasis during bacterial septic shock.
IL-6 signaling in rat brain
Our previous work (1) together with the present results suggest
that neural cells become more sensitive to IL-6 during systemic immune
challenges by increasing the number of receptor molecules on their
surface. Although this modification seems to be essential, additional
physiological changes might be required to allow such a permissive
effect. The shedding of soluble IL-6R, the alteration of the
blood-brain barrier (BBB), and the activation of transduction
pathways cooperating with those solicited by IL-6 are examples of
mechanisms that may amplify, widen, and prolong the IL-6 activities. On
the one hand, these changes may be initiated by the direct action of
LPS on endothelial and parenchymal cells after binding to its specific
receptor CD14. Indeed, we have recently demonstrated that CD14 is
distributed in brain regions accessible from the blood circulation
under basal conditions and that scattered microglial cells produce this
receptor within a few hours after LPS administration (31). Although the
endothelial cells do not express CD14, they can respond to circulating
endotoxin in a soluble CD14-dependent manner (32, 33, 34). On the other
hand, the enhancement of IL-6 signaling may be induced by
proinflammatory cytokines released by macrophages and glial cells in
response to LPS. It has been shown that systemically injected IL-1ß
is capable of stimulating IL-6R synthesis in cerebral blood vessels (1)
and that TNF
can modulate the expression of both IL-6R and gp130
mRNAs in cultured neurons (35). Moreover, as observed in the present
study, IL-6 can increase the levels of its receptor within perivascular
and parenchymal elements of the brain, an effect consistent with the
observation that IL-6 can up-regulate its receptor in the liver
(36).
IL-6 and the HPA axis
The presence of IL-6 is essential for coordinating a variety
of physiological responses during infections, but overexposition of the
nervous tissue to IL-6 induces a pronounced reactive gliosis and leads
to neurodegeneration associated with impaired learning capacities (22, 37, 38). Appropriate modulation of IL-6 signaling is thus not only
important for enhancing the effects of IL-6, but also to avoid its
deleterious actions. It is well known that IL-6 stimulates the HPA
axis, which provides negative feedback signals acting to reduce the
immune response in general and the secretion of IL-6 and other
proinflammatory cytokines in particular. IL-6 is thought to be a long
term regulator of plasma ACTH and glucocorticoid levels by acting
directly on the anterior pituitary (11, 12) and the adrenal gland
(13, 14, 15), respectively. Moreover, IL-6 can exert an acute stimulatory
effect on the HPA axis by acting on the hypothalamus to induce
infundibular CRF secretion (16, 17, 18). However, the importance of IL-6 in
this process was recently challenged by the demonstration that iv
injected IL-6 is unable by itself to activate PVN neurons and to
stimulate CRF gene transcription (10, 19), contrasting with the
capacity of IL-1ß (1) and TNF
(Nadeau, S., and S. Rivest,
unpublished results) to induce these changes. We prove here that IL-6
can, in fact, activate PVN neurons, but the cytokine seems to require
prior activation of the immune response and the synthesis of its
receptor. The present study also demonstrated that the increase in
plasma glucocorticoid levels at 1 h after iv IL-6 injection is
significant only in animals that were pretreated 6 h before with a
very low dose of LPS. It is interesting to note that coadministration
of IL-6 and IL-1ß results in synergistic activation of ACTH and
corticosterone release (39, 40, 41, 42). Although these effects may be caused
by the interaction of both cytokines in the peripheral glands and
despite IL-1ß is unable to induce IL-6R expression in the PVN (1), it
cannot be excluded that IL-1ß and IL-6 may cooperate in the brain to
modulate the HPA axis or other nervous functions. It will be exciting
in future work to characterize clearly the nature of these
interactions, but the fact that circulating IL-1ß is capable of
inducing IL-6R in blood vessels of the brain may be a crucial event
leading to such permissive action of the proinflammatory cytokine
(1).
Possible mechanisms of action
The exact mechanisms by which IL-6 stimulates PVN neurons
remain to be elucidate. The presence of IL-6R in some CRF neurons
offers the possibility that IL-6 may directly target these cells.
Alternatively, IL-6 may act on neurons devoid of IL-6R, but expressing
the signal transducer gp130, after binding its soluble receptor. At
first sight, these possibilities seem to be conflicting with the
current view that circulating cytokines cannot cross the BBB, but a
number of mechanisms may explain this discrepancy. First, PVN neurons
project to the median eminence and to the neurohypophysis, thereby
exposing their axon terminals to molecules circulating into the
bloodstream or secreted locally from cells of myeloid lineage. It has
been proposed that IL-6 may act within the median eminence to trigger
the release of CRF into the hypophyseal portal system (43). This is
supported by our recent observations that median eminence expresses the
IL-6R subunits and that iv injected IL-6 induces c-fos
expression in this region (1, 10). Second, excessive nitric oxide and
IL-6 production caused by endotoxin can alter cerebral endothelium
functions and disrupt the BBB (44). The resulting increase of
permeability may then allow high weight molecules, including cytokines,
to reach sites behind the BBB, but such a mechanism has been challenged
by numerous studies. Third, it has been demonstrated that a small
quantity of IL-6 can penetrate across the intact BBB via a transport
system distinct from those for IL-1ß and TNF
(45). Some brain
areas may, therefore, be equipped with an as yet uncharacterized active
transport for IL-6, which might be activated under stressful
circumstances. Forth, the choroid plexus is a cerebrospinal
fluid-synthesizing structure that has been pointed out as one of the
principal sources of central IL-6 during endotoxemia (1). After being
released into the ventricular system, centrally produced IL-6 may
circulate throughout the brain and reach PVN neurons through passive
diffusion.
In addition to the above mechanisms and given that many CRF neurons
seem not to express IL-6R, it is conceivable that IL-6 may stimulate
intermediate cells, such as endothelial or microglial cells, to release
paracrine factors that, in turn, could influence neuronal activity. As
potential candidates, PGs and nitric oxide are key mediators in
neuroimmune communication, and their production can be controlled by
IL-1ß and TNF
(46, 47, 48, 49). Unfortunately, depending on the
experimental procedure and the tissue studied, there are as many
studies that prove their involvement in mediating the central effects
of IL-6 as there are studies that are in disagreement with it. For
examples, it has been demonstrated that PGs mediate IL-6-induced fever
(8, 9, 50) and HPA axis stimulation (16, 17), but IL-6 is unable to
activate PG formation in cerebral microvessels (51) and to induce COX-2
mRNA synthesis in rat brains (29) or in cultured microglial cells (52).
It is clear, however, that IL-6 does not stimulate the production of
PGs in peripheral organs, and that, conversely, its own synthesis is
induced by them (53, 54). In agreement with the latter, it has recently
been shown that IL-6 expression in astrocytes can be induced in
vitro by PGE2 (55). Taking together, these
observations suggest that IL-6 does not stimulate COX-2 gene
transcription, but the possibility that IL-6 may influence PG synthesis
at posttranscriptional levels or may cooperate with them to activate
CRF neurons cannot be ruled out. On the other hand, much less
information is available regarding the effect of IL-6 on nitric oxide
production. It has been shown that IL-6 stimulates nitrite formation in
cultured hippocampal slices (56). However, IL-6-induced glial cell
growth (57) and neuroblastoma cell differentiation (49) are not
mediated by nitric oxide, and transgenic mice overexpressing IL-6 in
the brain do not manifest any increase in inducible nitric oxide
synthase gene expression (22). In light of the above observations, the
roles of PGs and nitric oxide in mediating the effects of IL-1ß and
TNF-
cannot be generalized to IL-6, and more detailed studies will
be needed to clarify the mechanisms by which this cytokine may affect
the neuroendocrine response.
Relative importance of IL-6 during endotoxemia
It is generally believed that proinflammatory cytokines released
by macrophages during endotoxemia are mainly responsible for the
stimulation of the HPA axis. The relative contribution of IL-6 in this
process is currently the subject of intense debates and investigations.
Accumulating data are, however, in disagreement with this view and
rather suggest that LPS may directly act within the hypothalamus to
activate PVN neurons without any help of systemic cytokines during the
early phases. Indeed, the levels of plasma ACTH and corticosterone are
increased in response to LPS before the elevation of circulating
IL-1ß, TNF
, and IL-6 (58). It is therefore not surprising that
pretreatment with IL-1ß antagonist or anti-TNF
antibody does not
abolish the LPS-induced HPA axis and that IL-6-deficient mice produce
normal corticosterone levels during the first hour after LPS injection
(41, 59, 60, 61). Thereafter, the increase in circulating corticosterone
levels has recently been found to be lower in IL-6-/-
than IL-6+/+ mice in response to ip LPS injection, but not
during restraint stress (62). This suggests that the involvement of
IL-6 in the control of the HPA axis is quite specific to the immune
stimuli and not to neurogenic stresses. The participation of IL-6 is
further suggested by the fact that pretreatment with anti-IL-6 antibody
abrogates ACTH secretion both 2 and 4 h after LPS administration,
but not at 1 h (41). This cytokine may be considered as a crucial
modulator of the HPA axis, as anti-IL-6 antibody also abolishes the
IL-1-induced increase in plasma ACTH (40). Interestingly, this
determining role has been confirmed in models using inflammatory agents
lacking the intrinsic capacity to stimulate the HPA axis, but able to
induce cytokine production. It was concluded that IL-6 is an obligate
factor to increase glucocorticoid production during cytomegalovirus
infection or after the injection of a synthetic analog of viral nucleic
acid (62).
The present study brings some light on the mechanisms by which IL-6
contributes to the regulation of the neuroendocrine response by
demonstrating that IL-6 is required during the later phases of
endotoxemia to sustain the activated state of CRF neurons controlling
the HPA axis. It is interesting to mention that IL-6 can also induce
the secretion of arginine vasopressin (AVP) (63, 64), an important ACTH
and corticosteroid secretagogue, and that chronic cerebral expression
of IL-6 modulates the stress-induced increase in plasma corticosterone
via a mechanism involving AVP (65). Given that the activation of neural
cells located in both parvocellular and magnocellular PVN was observed
in the present study after cotreatment with LPS and IL-6, it is
plausible that IL-6 stimulates both CRF and AVP neuroendocrine systems
during endotoxemia. An important point to address in future
investigations will be determination of the exact proportions of CRF-,
AVP- and CRF/AVP-activated neurons during the acute phase response in
both wild-type and IL-6-deficient mice.
Besides controlling the HPA axis, IL-6 induces a series of other
brain-mediated responses and participates in the modulation of local
inflammatory events. Over the past years, we used the protooncogene
c-fos to identify within the brain the sites of action of
the cytokine. We found that CVOs, the meninges, the ependymal cell
layer covering the ventricular spaces, and the portion of parenchyma
surrounding the ventricles are profoundly activated after an
intracerebroventricular injection of IL-6 (10). More recently, we
reported that IL-6 is not synthesized in the brain under basal
conditions, but is rapidly expressed by the choroid plexus and other
CVOs in response to systemically injected endotoxin. Furthermore, the
present study shows that LPS-induced c-fos expression is
markedly reduced in the brain of knockout animals, especially in
structures that were responding to the intracerebroventricular IL-6
treatment. Taken together, these observations suggest that IL-6 may be
secreted by the choroid plexus into cerebrospinal fluid, which diffuses
across the brain through the ventricles. This may allow the cytokine to
stimulate various neural cells, principally those associated with or
close to the ventricular system. The presence of IL-6R in parvocellular
neurons of the PVN is of great interest, as it suggests that IL-6 of
central origin may bind to its cognate receptor directly within the
endocrine hypothalamus. Such a mechanism obviously does not take place
in the brain of IL-6-deficient mice, which may contribute to the
reduced activity of PVN neurons during endotoxemia.
Conclusion
In summary, the following sequence of events presumably takes
place in the central nervous system during endotoxemia. Bacterial
endotoxin reaches the brain through the circulation and acts directly
on nonparenchymal and parenchymal structures accessible from the blood,
which leads to the activation of vascular-associated cells and
development of the inflammatory response. PVN neurons are also
activated in presence of LPS and respond by increasing the
transcription of the gene encoding CRF, the neurosecretagogue that
controls the HPA axis. A variety of neural cells become gradually more
sensitive to IL-6, mainly by expressing more receptor molecules on
their surface. When it becomes available, IL-6 maintains the activation
state of the hypothalamic CRF neurons and participates in specific
cellular responses necessary for eliminating the endotoxin. Centrally
produced IL-6 may also play local roles in regulating inflammatory
processes and can serve as a neuroprotective signal after being
released into cerebrospinal fluid. As a consequence, the inflammation
can be properly controlled by the inhibitory effects of
glucocorticoids on cytokine expression.
 |
Acknowledgments
|
|---|
We thank Dr. M. Kopf (Basel Institute for Immunology,
Basel, Switzerland) for the generous gift of IL-6-deficient mice, Dr.
I. Verma (The Salk Institute, La Jolla, CA) for the rat
c-fos cDNA, Dr. K. Mayo (Northwestern University, Evanston,
IL) for the rat CRF cDNA, Dr. S. Watson (University of Michigan, Ann
Arbor, MI) for the rat intronic CRF cDNA, and Dr. K. Peri
(Sainte-Justine Hospital Research Center, Montreal, Canada) for the rat
COX-2 cDNA. We also thank Nathalie Laflamme, Nicole Martel, and
René Labrecque for invaluable technical assistance.
 |
Footnotes
|
|---|
1 This work was supported by the Medical Research Council of
Canada. 
2 Supported by Ph.D. studentships from the Natural Sciences and
Engineering Research Council of Canada and the Fonds pour la Formation
des Chercheurs et lAide à la Recherche du Québec.
Presently a postdoctoral fellow at The Salk Institute (La Jolla,
CA). 
3 Medical Research Council Scientist. 
Received December 1, 1998.
 |
References
|
|---|
-
Vallières L, Rivest S 1997 Regulation of
the genes encoding interleukin-6, its receptor, and gp130 in the rat
brain in response to the immune activator lipopolysaccharide and the
proinflammatory cytokine interleukin-1ß. J Neurochem 69:16681683[Medline]
-
Quan N, Whiteside M, Herkenham M 1998 Time course
and localization patterns of interleukin-1ß messenger RNA expression
in brain and pituitary after peripheral administration of
lipopolysaccharide. Neuroscience 83:281293[CrossRef][Medline]
-
Breder CD, Hazuka C, Ghayur T, Klug C, Huginin M,
Yasuda K, Teng M, Saper CB 1994 Regional induction of tumor
necrosis factor alpha expression in the mouse brain after systemic
lipopolysaccharide administration. Proc Natl Acad Sci USA 91:1139311397[Abstract/Free Full Text]
-
Besedovsky HO, Del Rey A 1996 Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 17:64102[CrossRef][Medline]
-
Rothwell NJ, Hopkins SJ 1995 Cytokines and the
nervous system. II. Actions and mechanisms of action. Trends Neurosci 18:130136[CrossRef][Medline]
-
Schöbitz B, De Kloet ER, Holsboer F 1994 Gene expression and function of interleukin 1, interleukin 6 and tumor
necrosis factor in the brain. Prog Neurobiol 44:397432[CrossRef][Medline]
-
Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T 1996 Interleukin (IL)-6 gene expression in the central nervous system
is necessary for fever response to lipopolysaccharide or IL-1ß: a
study on IL-6-deficient mice. J Exp Med 183:311316[Abstract/Free Full Text]
-
Dinarello CA, Cannon JG, Mancilla J, Bishai I,
Lees J, Coceani F 1991 Interleukin-6 as an endogenous pyrogen:
induction of prostaglandin E2 in brain but not in peripheral blood
mononuclear cells. Brain Res 562:199206[CrossRef][Medline]
-
Fernandez-Alonso A, Benamar K, Sancibrian M,
Lopez-Valpuesta FJ, Minano FJ 1996 Role of interleukin-1ß,
interleukin-6 and macrophage inflammatory protein-1ß in
prostaglandin-E2-induced hyperthermia in rats. Life Sci
59:L185190
-
Vallières L, Lacroix S, Rivest S 1997 Influence of interleukin-6 on neural activity and transcription of the
gene encoding corticotropin-releasing factor in the rat brain: an
effect depending upon the route of administration. Eur J Neurosci 9:14611472[CrossRef][Medline]
-
Fukata J, Usui T, Naitoh Y, Nakai Y, Imura H 1989 Effects of recombinant human interleukin-1
, -1ß, 2 and 6 on ACTH
synthesis and release in the mouse pituitary tumour cell line AtT-20. J
Endocrinol 122:3339[Abstract]
-
Lyson K, McCann SM 1991 The effect of interleukin-6
on pituitary hormone release in vivo and in vitro. Neuroendocrinology 54:262266[Medline]
-
Salas MA, Evans SW, Levell MJ, Whicher JT 1990 Interleukin-6 and ACTH act synergistically to stimulate the release of
corticosterone from adrenal gland cells. Clin Exp Immunol 79:470473[Medline]
-
Path G, Bornstein SR, Ehrhart B-M, Scherbaum WA 1997 Interleukin-6 and the interleukin-6 receptor in the human adrenal
gland: expression and effects on steroidogenesis. J Clin
Endocrinol Metab 82:23432349[Abstract/Free Full Text]
-
Weber MM, Michl P, Auernhammer CJ, Engelhardt D 1997 Interleukin-3 and interleukin-6 stimulate cortisol secretion from
adult human adrenocortical cells. Endocrinology 138:22072210[Abstract/Free Full Text]
-
Navarra P, Tsagarakis S, Faria MS, Rees LH, Besser GM,
Grossman AB 1991 Interleukins-1 and -6 stimulate the release of
corticotropin-releasing hormone-41 from rat hypothalamus in vitro via
the eicosanoid cyclooxygenase pathway. Endocrinology 128:3744[Abstract]
-
Lyson K, McCann SM 1992 Involvement of arachidonic
acid cascade pathways in interleukin-6-stimulated
corticotropin-releasing factor release in vitro. Neuroendocrinology 55:708713[Medline]
-
Naitoh Y, Fukata J, Tominaga T, Nakai Y, Tamai S,
Mori K, Imura H 1988 Interleukin-6 stimulates the secretion of
adrenocorticotropic hormone in conscious, freely-moving rats.
Biochem Biophys Res Commun 155:14591463[CrossRef][Medline]
-
Harbuz MS, Stephanou A, Sarlis N, Lightman SL 1992 The effects of recombinant human interleukin (IL)-1
, IL-1ß or IL-6
on hypothalamo-pituitary-adrenal axis activation. J Endocrinol 133:349355[Abstract]
-
LeMay LG, Vander AJ, Kluger MJ 1990 Role of
interleukin 6 in fever in rats. Am J Physiol 258:R798R803
-
Klein MA, Moller JC, Jones LL, Bluethmann H,
Kreutzberg GW, Raivich G 1997 Impaired neuroglial activation in
interleukin-6 deficient mice. Glia 19:227233[CrossRef][Medline]
-
Chiang CS, Stalder A, Samimi A, Campbell IL 1994 Reactive gliosis as a consequence of interleukin-6 expression in the
brain: studies in transgenic mice. Dev Neurosci 16:212221[Medline]
-
Balasingam V, Tejada B-T, Wright E, Bouckova R, Yong
VW 1994 Reactive astrogliosis in the neonatal mouse brain and its
modulation by cytokines. J Neurosci 14:846856[Abstract]
-
Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF,
Achong MK 1998 IL-6 is an antiinflammatory cytokine required for
controlling local or systemic acute inflammatory responses. J Clin
Invest 101:311320[Medline]
-
Sterneck E, Kaplan DR, Johnson PF 1996 Interleukin-6 induces expression of peripherin and cooperates with Trk
receptor signaling to promote neuronal differentiation in PC12 cells.
J Neurochem 67:13651374[Medline]
-
Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M,
Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G 1994 Impaired
immune and acute-phase responses in interleukin-6-deficient mice.
Nature 368:339342[CrossRef][Medline]
-
Simmons DM, Arriza JL, Swanson LW 1989 A complete
protocol for in situ hybridization of messenger RNAs in
brain and other tissues with radio-labeled single-stranded RNA probes.
J Histotechnol 12:169181
-
Swanson LW 1992 Brain Maps: Structure of the Rat
Brain. Elsevier, New York, p 240
-
Lacroix S, Rivest S 1998 Effect of acute systemic
inflammatory response and cytokines on the transcription of the genes
encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain.
J Neurochem 70:452466[Medline]
-
Rivest S, Laflamme N 1995 Neuronal activity
and neuropeptide gene transcription in the brains of immune-challenged
rats. J Neuroendocrinol 7:501525[CrossRef][Medline]
-
Lacroix S, Feinstein D, Rivest S 1998 The bacterial
endotoxin lipopolysaccharide has the ability to target the brain in
upregulating its membrane CD14 receptor within specific cellular
populations. Brain Pathol 8:625640[Medline]
-
Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A,
Ulevitch RJ, Tobias PS 1993 Lipopolysaccharide activation of human
endothelial and epithelial cells is mediated by
lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci
USA 90:27442748[Abstract/Free Full Text]
-
Arditi M, Zhou J, Dorio R, Rong GW, Goyert SM, Kim
KS 1993 Endotoxin-mediated endothelial cell injury and activation:
role of soluble CD14. Infect Immun 61:31493156[Abstract/Free Full Text]
-
Haziot A, Rong GW, Silver J, Goyert SM 1993 Recombinant soluble CD14 mediates the activation of endothelial cells
by lipopolysaccharide. J Immunol 151:15001507[Abstract]
-
Marz P, Gadient RA, Otten U 1996 Expression of
interleukin-6 receptor (IL-6R) and gp130 mRNA in PC12 cells and
sympathetic neurons: modulation by tumor necrosis factor
(TNF-
).
Brain Res 706:7179[CrossRef][Medline]
-
Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T 1992 Molecular cloning of a murine IL-6 receptor-associated signal
transducer, gp130, and its regulated expression in vivo. J Immunol 148:40664071[Abstract]
-
Campbell IL, Abraham CR, Masliah E, Kemper P,
Inglis JD, Oldstone MB, Mucke L 1993 Neurologic disease induced in
transgenic mice by cerebral overexpression of interleukin 6. Proc
Natl Acad Sci USA 90:1006110065[Abstract/Free Full Text]
-
Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold
LH 1997 Progressive decline in avoidance learning paralleled by
inflammatory neurodegeneration in transgenic mice expressing
interleukin 6 in the brain. Proc Natl Acad Sci USA 94:15001505[Abstract/Free Full Text]
-
Perlstein RS, Mougey EH, Jackson WE, Neta R 1991 Interleukin-1 and interleukin-6 act synergistically to stimulate the
release of adrenocorticotropic hormone in vivo. Lymphokine Cytokine Res 10:141146[Medline]
-
Neta R, Perlstein R, Vogel SN, Ledney GD, Abrams J 1992 Role of interleukin 6 (IL-6) in protection from lethal irradiation
and in endocrine responses to IL-1 and tumor necrosis factor. J Exp Med 175:689694[Abstract/Free Full Text]
-
Perlstein RS, Whitnall MH, Abrams JS, Mougey EH, Neta
R 1993 Synergistic roles of interleukin-6, interleukin-1, and
tumor necrosis factor in the adrenocorticotropin response to bacterial
lipopolysaccharide in vivo. Endocrinology 132:946952[Abstract]
-
Zhou D, Shanks N, Riechman SE, Liang R, Kusnecov
AW, Rabin BS 1996 Interleukin 6 modulates interleukin-1-and
stress-induced activation of the hypothalamic-pituitary-adrenal axis in
male rats. Neuroendocrinology 63:227236[Medline]
-
Spinedi E, Hadid R, Daneva T, Gaillard RC 1992 Cytokines stimulate the CRH but not the vasopressin neuronal system:
evidence for a median eminence site of interleukin-6 action.
Neuroendocrinology 56:4653[Medline]
-
Brett FM, Mizisin AP, Powell HC, Campbell IL 1995 Evolution of neuropathologic abnormalities associated with blood-brain
barrier breakdown in transgenic mice expressing interleukin-6 in
astrocytes. J Neuropathol Exp Neurol 54:766775[Medline]
-
Banks WA, Kastin AJ, Gutierrez EG 1994 Penetration
of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 179:5356[CrossRef][Medline]
-
Ericsson A, Arias C, Sawchenko PE 1997 Evidence for an intramedullary prostaglandin-dependent mechanism in the
activation of stress-related neuroendocrine circuitry by intravenous
interleukin-1. J Neurosci 17:71667179[Abstract/Free Full Text]
-
Dayer JM, Beutler B, Cerami A 1985 Cachectin/tumor
necrosis factor stimulates collagenase and prostaglandin E2 production
by human synovial cells and dermal fibroblasts. J Exp Med 162:21632168[Abstract/Free Full Text]
-
Rivier C, Shen GH 1994 In the rat, endogenous
nitric oxide modulates the response of the
hypothalamic-pituitary-adrenal axis to interleukin-1ß, vasopressin,
and oxytocin. J Neurosci 14:19851993[Abstract]
-
Munoz-Fernandez MA, Cano E, ODonnell CA, Doyle J, Liew
FY, Fresno M 1994 Tumor necrosis factor-
(TNF-
),
interferon-
, and interleukin-6 but not TNF-ß induce
differentiation of neuroblastoma cells: the role of nitric oxide.
J Neurochem 62:13301336[Medline]
-
Xin L, Blatteis CM 1992 Hypothalamic neuronal
responses to interleukin-6 in tissue slices: effects of indomethacin
and naloxone. Brain Res Bull 29:2735[CrossRef][Medline]
-
Bishai I, Coceani F 1996 Differential effects of
endotoxin and cytokines on prostaglandin E2 formation in cerebral
microvessels and brain parenchyma: implications for the pathogenesis of
fever. Cytokine 8:371376[CrossRef][Medline]
-
Bauer MK, Lieb K, Schulze-Osthoff K, Berger M,
Gebicke-Haerter PJ, Bauer J, Fiebich BL 1997 Expression and
regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem 243:726731[Medline]
-
Hinson RM, Williams JA, Shacter E 1996 Elevated
interleukin 6 is induced by prostaglandin E2 in a murine model of
inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 93:48854890[Abstract/Free Full Text]
-
Williams JA, Shacter E 1997 Regulation of
macrophage cytokine production by prostaglandin E2. Distinct roles of
cyclooxygenase-1 and -2. J Biol Chem 272:2569325699[Abstract/Free Full Text]
-
Fiebich BL, Hull M, Lieb K, Gyufko K, Berger M, Bauer
J 1997 Prostaglandin E2 induces interleukin-6 synthesis in human
astrocytoma cells. J Neurochem 68:704709[Medline]
-
Ma T, Zhu X 1997 Interleukin-6 increases the levels
of cyclic GMP and nitrite in rat hippocampal slices. Eur J
Pharmacol 321:343347[CrossRef][Medline]
-
Munoz-Fernandez MA, Fresno M 1993 Involvement of
nitric oxide on the cytokine induced growth of glial cell. Biochem
Biophys Res Commun 194:319325[CrossRef][Medline]
-
Givalois L, Dornand J, Mekaouche M, Solier MD, Bristow
AF, Ixart G, Siaud P, Assenmacher I, Barbanel G 1994 Temporal
cascade of plasma level surges in ACTH, corticosterone, and cytokines
in endotoxin-challenged rats. Am J Physiol 267:R164R170
-
Dunn AJ 1992 The role of interleukin-1 and tumor
necrosis factor
in the neurochemical and neuroendocrine responses
to endotoxin. Brain Res Bull 29:807812[CrossRef][Medline]
-
Paez Pereda M, Sauer J, Perez Castro C, Finkielman S,
Stalla GK, Holsboer F, Arzt E 1995 Corticotropin-releasing hormone
differentially modulates the interleukin-1 system according to the
level of monocyte activation by endotoxin. Endocrinology 136:55045510[Abstract]
-
Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni
L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V 1994 Defective inflammatory response in interleukin 6-deficient mice. J Exp
Med 180:12431250[Abstract/Free Full Text]
-
Ruzek MC, Miller AH, Opal SM, Pearce BD, Biron CA 1997 Characterization of early cytokine responses and an interleukin
(IL)-6-dependent pathway of endogenous glucocorticoid induction during
murine cytomegalovirus infection. J Exp Med 185:11851192[Abstract/Free Full Text]
-
Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos
GP 1994 Hypothalamic-pituitary-adrenal axis activation and
stimulation of systemic vasopressin secretion by recombinant
interleukin-6 in humans: potential implications for the syndrome of
inappropriate vasopressin secretion. J Clin Endocrinol Metab 79:934939[Abstract]
-
Kageyama K, Watanobe H, Takebe K 1995 In vivo
evidence that arginine vasopressin is involved in the
adrenocorticotropin response induced by interleukin-6 but not by tumor
necrosis factor-
in the rat. Neuroimmunomodulation 2:137140[CrossRef][Medline]
-
Raber J, OShea RD, Bloom FE, Campbell IL 1997 Modulation of hypothalamic-pituitary-adrenal function by transgenic
expression of interleukin-6 in the CNS of mice. J Neurosci 17:94739480[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
K. Kageyama, K. Hanada, Y. Iwasaki, S. Sakihara, T. Nigawara, J. Kasckow, and T. Suda
Pituitary adenylate cyclase-activating polypeptide stimulates corticotropin-releasing factor, vasopressin and interleukin-6 gene transcription in hypothalami |